Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)94.45
  • Today's Change-0.40 / -0.42%
  • Shares traded31.44k
  • 1 Year change-52.76%
  • Beta1.8490
Data delayed at least 15 minutes, as of Sep 30 2022 05:20 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • DCAL:NSI price reached a new 52-week low of 92.10 at 13:19 BST
  • DCAL:NSI price reached a new 52-week low of 93.70 at 12:34 BST
  • DCAL:NSI price moved over -3.80% to 93.70
  • DCAL:NSI trading volume exceeds daily average by +29.82%

Key statistics

As of last trade Dishman Carbogen Amcis Ltd (DCAL:NSI) traded at 94.45, 4.83% above its 52-week low of 90.10, set on Sep 27, 2022.
52-week range
90.10Sep 27 2022259.70Oct 07 2021
Previous close94.85
Average volume710.90k
Shares outstanding156.78m
Free float48.11m
P/E (TTM)245.16
Market cap14.68bn INR
EPS (TTM)0.382
Data delayed at least 15 minutes, as of Sep 30 2022 05:20 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.